BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32843993)

  • 1. Acromegaly: a clinical perspective.
    Lawrence L; Alkwatli K; Bena J; Prayson R; Kshettry V; Recinos P; Hatipoglu B; Pantalone KM; Weil R; Hamrahian AH; Kennedy L; Yogi-Morren D
    Clin Diabetes Endocrinol; 2020; 6():15. PubMed ID: 32843993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature.
    Almeida JP; Ruiz-Treviño AS; Liang B; Omay SB; Shetty SR; Chen YN; Anand VK; Grover K; Christos P; Schwartz TH
    J Neurosurg; 2018 Aug; 129(2):404-416. PubMed ID: 28862548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
    Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
    Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly.
    Jung IH; Choi S; Ku CR; Lee SG; Lee EJ; Kim SH; Kim EH
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2589-e2599. PubMed ID: 33738470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes.
    Rick J; Jahangiri A; Flanigan PM; Chandra A; Kunwar S; Blevins L; Aghi MK
    J Neurosurg; 2018 Sep; 131(1):147-153. PubMed ID: 30215558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
    Schwyzer L; Starke RM; Jane JA; Oldfield EH
    J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study.
    Dehghani M; Davoodi Z; Bidari F; Moghaddam AM; Khalili D; Bahrami-Motlagh H; Jamali E; Alamdari S; Hosseinpanah F; Hedayati M; Valizadeh M
    BMC Endocr Disord; 2021 Sep; 21(1):186. PubMed ID: 34530798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
    Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.
    Nagata Y; Inoshita N; Fukuhara N; Yamaguchi-Okada M; Nishioka H; Iwata T; Yoshimoto K; Yamada S
    Pituitary; 2018 Feb; 21(1):1-9. PubMed ID: 28849339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY.
    Anthony JR; Alwahab UA; Kanakiya NK; Pontell DM; Veledar E; Oyesiku NM; Ioachimescu AG
    Endocr Pract; 2015 Sep; 21(9):1001-9. PubMed ID: 26121434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes.
    Nishioka H; Fukuhara N; Horiguchi K; Yamada S
    J Neurosurg; 2014 Sep; 121(3):505-10. PubMed ID: 25014437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
    Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
    Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis.
    Briceno V; Zaidi HA; Doucette JA; Onomichi KB; Alreshidi A; Mekary RA; Smith TR
    Neurol Res; 2017 May; 39(5):387-398. PubMed ID: 28301972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
    Kaltsas GA; Isidori AM; Florakis D; Trainer PJ; Camacho-Hubner C; Afshar F; Sabin I; Jenkins JP; Chew SL; Monson JP; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1645-52. PubMed ID: 11297598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature.
    Minniti G; Jaffrain-Rea ML; Esposito V; Santoro A; Tamburrano G; Cantore G
    Endocr Relat Cancer; 2003 Dec; 10(4):611-9. PubMed ID: 14713271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.